NLS Pharmaceutics (NLSP) has released an update.
NLS Pharmaceutics has announced a definitive merger agreement with Kadimastem, a cell therapy company, to enhance its Dual Orexin Agonist platform and Kadimastem’s cell therapy program targeting diabetes and ALS. This strategic move, expected to close in January 2025, will see NLS divesting its legacy assets and redistributing proceeds to shareholders, while Kadimastem will gain exposure to U.S. capital markets through a Nasdaq listing. The merger aims to strengthen the combined company’s position in the promising field of neurodegenerative and diabetes treatments.
For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.
